Nurix Therapeutics, Inc. (NRIX) Stock Price & Analysis

Nurix Therapeutics, Inc. (NRIX) rose 0.00% to USD 15.64 as of June 10, 2026 at 02:00 UTC, according to Nexqual real-time market data.

NRIX last closed at USD 15.64; the session ranged USD 14.67–16.99 on volume of 6,596,807 shares. Market capitalization is $1.62B, with a 52-week range of USD 8.2–22.5 (NGM). Source: Nexqual, June 10, 2026 at 02:00 UTC.

Key Statistics (as of June 10, 2026 at 02:00 UTC)

Technical Analysis (NRIX)

Nexqual's technical model rates NRIX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:00 UTC.

Analyst Ratings (NRIX)

Wall Street analysts rate NRIX "Strong Buy" based on 17 analysts, with a mean price target of USD 30.94 (range USD 23–45), per Nexqual as of June 10, 2026 at 02:00 UTC.

Earnings (NRIX)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:00 UTC.

Financials & Fundamentals (NRIX)

Source: Nexqual, June 10, 2026 at 02:00 UTC.

Financial Health Score (NRIX)

Nexqual rates Nurix Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:00 UTC.

Ownership (NRIX)

Source: Nexqual, June 10, 2026 at 02:00 UTC.

Leadership (NRIX)

Nurix Therapeutics, Inc. is led by Arthur T. Sands (age 63), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:00 UTC.

Major Backers & Investors (NRIX)

Notable institutional backers of Nurix Therapeutics, Inc. include Redmile Group, LLC, Vestal Point Capital, LP, Deep Track Capital, Lp, according to Nexqual as of June 10, 2026 at 02:00 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:00 UTC.

From Nurix Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-01-28)

Key Strengths & Strategy (as disclosed to the SEC)

• We expect to earn multiple additional preclinical and clinical milestones across our three active partnerships in 2026, which may allow us to secure additional license and development candidate events in 2026 and subsequent years. • Advance our proprietary portfolio of preclinical programs toward additional INDs.
• By combining Nurix's experience in machine learning, automated chemistry and targeted protein degraders with Pfizer's expertise in antibody conjugate design, optimization and development, we believe we can achieve technical synergies that could allow us to redefine the application of antibody conjugates for not only oncology but also non-oncology indications. 7 • Grow our proprietary pipeline by expanding the capabilities of our DEL-AI platform.
• Based on reported sales to date, global sales of this drug class, including Revlimid and Pomalyst, peaked in 2021 at approximately $16.2 billion, prior to the introduction of generic competition.
• Our approach uses comprehensive parallel screening campaigns to interrogate numerous states and surfaces of the target protein by combining multiple protein constructs with a variety of known substrates, binders, or cofactors in empirically replicated screening assays . • Proprietary data analysis and hit confirmation technologies .

Partnerships

• In our partnership with Pfizer, which was announced in September 2023 under an agreement with Seagen, Inc., we have achieved three preclinical milestones to date, qualifying for $15.0 million in milestone payments.
• As part of our strategy to accelerate DAC discovery and demonstrate value, we have partnered with Pfizer, the leading pharmaceutical company in the antibody drug conjugate space, to advance this cutting-edge modality.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:00 UTC. This page is informational and not investment advice.